A Multicenter, Prospective Observational Study to Evaluate the Incidence of Delayed-onset Nodules of YVOIRE Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 Injected Into the Facial Skin Layer.

LG Chem

Status: Completed

Conditions: Healthy Condition

Treatments: Diagnostic Test: Medical examination or treatment.

Study type: Observational

Funder types: Industry

Identifiers

NCT04738019

LG-HAOS007

Details and patient eligibility

About

This is an observational study to evaluate the incidence of delayed-onset nodules of YVOIRE Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 injected into the facial skin layer.

Enrollment: 1,022 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Planned for YVOIRE Y-Solution 360 or 540 or 720 filler injection in facial area (except middle of the forehead, lips) for the volume enhancement or anti-wrinkle treatment.
• Male and female of 19 years or above age.
• Informed consent to participate in the study.
• Able to participate throughout the study period.

Exclusion criteria

• Prohibited in the Product Label.
• Have active or infectious skin disease in injection area.
• Autoimmune disease or HIV infected patient.
• Received immunosuppressive therapy within 2 weeks.
• Previously experienced Delayed-onset nodule after filler injection in facial area.
• Previously experienced Hypertrophic scar or Keloid.
• Have participated in an interventional clinical investigation within 30 days or plan to participate one during the study period.
• Ineligible for this clinical investigation as per Investigator's discretion.